TOVX Theriva Biologics, Inc.
$0.19▼ -1.33%
Healthcare
Other
Volume 410.1K
Avg Volume (10D) 531.2K
Key Metrics & Fundamentals
Market Cap
$8.88M
P/E Ratio
0.3
Div Yield
0.00%
52W Range
0.16 - 0.49
% vs 50 MA
-15.58%
% vs 200 MA
-19.48%
RSI-14
35.9
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.72
Free Cash Flow
-$3.09M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.27M
COGS
–
Operating Exp
$3.30M
Operating Income
-$3.30M
EBIT
-$3.30M
Pretax Income
-$3.22M
Net Income
-$3.22M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
GlobeNewswire · Sep 30, 2026 8:00 AM ET
Theriva Biologics: Q2 Earnings Snapshot
Associated Press · Aug 11, 2026 8:07 AM ET
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
GlobeNewswire · Aug 11, 2026 8:00 AM ET
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
GlobeNewswire · Aug 6, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See TOVX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.